Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib + Everolimus in Relapsed/Refractory Classical Hodgkin Lymphoma
NCT03697408Phase 2Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Feb 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of itacitinib in classical Hodgkin lymphoma (cHL), sponsored by University of Pennsylvania. Started Feb 2019; status: active, not recruiting.
02
Drugs
itacitinib
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03697408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697408.